Sage Journals: Discover world-class research

Abstract

This case series describes the clinical course of 10 patients who received eravacycline antimicrobial therapy for a variety of different Acinetobacter baumannii infection types at a community care hospital.

Keywords

infectious disease eravacycline acinetobacter baumannii acinetobacter

Get full access to this article

View all access options for this article.

References

Acinetobacter in healthcare settings. Centers of Disease Control and Prevention. Updated November 13, 2019. Accessed June 13, 2022. https://www.cdc.gov/hai/organisms/acinetobacter.html

Heaney

Mahoney

Gallagher

. Eravacycline: The tetracyclines strike back. Ann Pharmacother. 2019;53(11):1124-1135.

Eravacycline [package insert]. Watertown, MA: Tetraphase Pharmaceuticals, Inc.;2018.

Tamma

Aitken

Bonomo

Mathers

van Duin

Clancy CJ

. IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections: Version 2.0. Infectious Diseases Society of America; 2022.

Alosaimy

Molina

Claeys

, et al. Early experience with eravacycline for complicated infections. Open Forum Infect Dis. 2020;7(5):ofaa071.

Use of Eravacycline for Acinetobacter baumannii Infections: A Case Series

Abstract

Keywords

Get full access to this article

References